Kyntra Bio, Inc. (KYNB) stock
Close on Nov 12, 2026Market cap $14.54MP/E 0.1Yield –
Kyntra Bio, Inc. saw revenue fall 37.1% to $4.62M over the twelve months to Jun 30, 2026. Free cash flow was -$38.06M. At the latest close the market valued the company at $14.54M, 0.1 times its earnings.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $14.54M
- P/E ratio
- 0.1
- Price to sales
- 3.15
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- -261.84%
Fundamentals
- Revenue
- $4.62M
- Net income
- $183.19M
- EPS, diluted
- $45.30
- Free cash flow
- -$38.06M
- Book value per share
- -$7.45
- Diluted shares
- 4M
Trading
- Next earnings
- Q3 FY2026, expected soon
- Previous close
- $3.68
- Open
- $3.67
- Day's range
- $3.52 – $3.77
- Volume
- 6,978
- Average volume (20 days)
- 23,735
- Beta (5 years)
- 1.26
- 52-week range
- $3.50 – $11.09
- RSI (14 days)
- 26.0
- Volatility (1 year)
- 56.6%
- Relative volume
- 0.96×
- WACC
- 11.2%
Market cap history
Month-end market cap since 2014, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 12, 2026. The S&P 500 is measured by the SPY fund.
| Period | KYNB | S&P 500 | Difference | KYNB per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -41.3% | -2.7% | −38.6 pts | ||
| 3 months | -49.4% | -1.7% | −47.7 pts | ||
| Year to date | -59.1% | +11.9% | −71.0 pts | ||
| 1 year | -60.7% | +12.0% | −72.7 pts | ||
| 3 years | -62.2% | +78.2% | −140.4 pts | -27.7% | +21.2% |
| 5 years | -98.8% | +73.2% | −172.0 pts | -58.8% | +11.6% |
| 10 years | -99.4% | +309.6% | −409.0 pts | -39.7% | +15.1% |
Fourteen years at a glance
Fiscal years 2012 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Kyntra Bio filed with the SEC as exhibits to Form 8-K or 6-K
- Update
- Results
- Results
- Results
- News
- Results
About Kyntra Bio
Pharmaceutical Preparations
Kyntra Bio, Inc. is a biopharmaceutical company engaged in the research, clinical development, and commercialization of pharmaceutical drug candidates. The company operates through business streams that include drug product manufacturing and supply as well as research, development, and licensing arrangements. Its primary lead product candidates comprise roxadustat and FG-3246, which is developed in conjunction with the positron emission tomography imaging agent FG-3180. Its principal customers and commercial counterparties include major multinational pharmaceutical partners such as Astellas and AstraZeneca, who collaborate on product development and commercial distribution.
Company profile, executives and historyKyntra Bio stock: common questions
What is Kyntra Bio's stock price?
KYNB closed at $3.59 on Nov 12, 2026, down 2.45% on the day. Over the past 52 weeks it traded between $3.50 and $11.09.
What is Kyntra Bio's market cap?
Kyntra Bio was worth $14.54M at the close on Nov 12, 2026: the share price times the diluted shares outstanding.
What is KYNB's P/E ratio?
KYNB trades at 0.1 times earnings, based on diluted earnings per share of $45.30 over the twelve months to Jun 30, 2026.
How much revenue does Kyntra Bio make?
Kyntra Bio reported revenue of $4.62M for the twelve months to Jun 30, 2026, down 37.1% from a year earlier.
Does Kyntra Bio pay a dividend?
No. Kyntra Bio has not paid a cash dividend over the last twelve months.
When does Kyntra Bio report earnings next?
Kyntra Bio's Q3 FY2026 results are due soon; the company has not yet filed them with the SEC.
How has KYNB stock performed over the past year?
Including dividends, KYNB returned -60.7% over the past year, against +12.0% for the S&P 500.
How many KYNB shares are sold short?
0M shares were sold short at the latest FINRA report, 2.81% of the float, or 4.7 days of average trading volume.
Who are Kyntra Bio's competitors?
Companies most similar to Kyntra Bio by business, industry and size include APLM, ANL, CNTB, TRAW, BOLT.
See a number that looks wrong?